Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma

HIGHLIGHTS

• who: Xiang Zhou from the DepartmentMedical University have published the research work: Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma, in the Journal: Scientific Reports Scientific Reports
• what: The authors analyzed ICD-related biomarkers in LUAD and constructed an ICD prognostic model, which might be an easy and reliable tool for deciding treatment regimens (immunotherapy, other novel therapy, or combinations), leading to better outcomes. Tumor immune dysfunction and exclusion (TIDE) (http://u200btide.u200bdfci.u200b harvau200brd.u200bedu/) analysis was conducted to evaluate the immunotherapy response. A . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.